# Wegovy口服藥丸是首款獲批用於體重管理的口服胰高血糖素樣肽-1（GLP-1）受體激動劑療法。

*biotech · news · 2026-06-07 · MarketScreener*

## Key points

- 阿聯酋是美國以外首個推出Wegovy口服藥丸的國家。
- Wegovy口服藥丸的減重效果與注射型Wegovy相似，平均減重約17%。
- 在OASIS 4試驗中，三分之一的參與者體重減輕達20%或以上。
- Wegovy口服藥丸是唯一獲得FDA和EDE批准用於降低主要心血管不良事件（MACE）風險的減重藥物。

Novo Nordisk announced the launch of Wegovy pill (semaglutide tablets) in the United Arab Emirates (UAE), the first country outside the United States to make the Wegovy pill available to people living with obesity. The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS 4 trial programme. In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated ~17% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities. The weight loss achieved with the Wegovy pill is similar to that of injectable Wegovy 2.4 mg. Furthermore, 1 in 3 people experienced 20% or greater weight loss in the OASIS 4 trial. The established safety and tolerability profile of semaglutide was reaffirmed with Wegovy pill in the OASIS-4 trial, which was comparable to previous trials with semaglutide for weight management. Wegovy pill is also the only weight-loss pill approved by both the FDA and the Emirates Drug Establishment (EDE) to reduce the risk of major adverse cardiovascular events (MACE), including heart attack and stroke, in adults with established cardiovascular disease and obesity or overweight. Novo Nordisk has previously announced that we will launch Wegovy pill in select markets in the second half of 2026.

**Companies:** Novo Nordisk
**Countries:** United Arab Emirates, United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/novo-nordisk-launches-wegovy-pill-in-the-united-arab-emirates-ce7f5dd2dc88f126)

---

Canonical: https://newsio.io/zh-TW/n/8b6a9b29-464c-43da-81b2-e758f304c884/wegovy-1glp-1oasis-42517
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works